Articles related to RETINA

Vigabatrin can cause irreversible peripheral retinal toxicity that is often asymptomatic, underscoring the need for consistent ophthalmic monitoring in treated patients.

FDA approval of 20‑week dosing for Eylea HD offers eligible wAMD and DME patients the potential for fewer injections while maintaining long‑term visual outcomes.

According to Elizabeth Cifers, MBA, a practice management consultant specializing in retina practice: “The key is to focus on medical necessity for the information the test will provide, rather than ordering an OCTA routinely.”

“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.”
— Christopher Viehbacher, President and CEO, Biogen

“These findings support the role of OCTA as an adjunctive tool for monitoring [hydroxychloroquine-induced] retinal changes, while further longitudinal studies are needed to clarify its predictive value.” – Study authors

The specialty treats a diverse patient population and the scientific discourse should reflect that breadth of experience and insight. Breaking these patterns requires intentional effort and sustained commitment.